Protecting Biopharmaceutical Innovation Litigation and Patent Office Procedures

Similar documents
Post-Grant Patent Proceedings

USPTO Post Grant Trial Practice

Inter Partes and Covered Business Method Reviews A Reality Check

AIA Post-Grant Proceedings: Evolution of the Rules. Rachel A. Kahler, Ph.D. Patent Agent General Mills, Inc.

New Post Grant Proceedings: Basics by

USPTO Post Grant Proceedings

Venue Differences. Claim Amendments During AIA Proceedings 4/16/2015. The Patent Trial and Appeal Board

POST GRANT REVIEW PROCEEDINGS IN THE PTO STEPHEN G. KUNIN PARTNER

Post-Grant Proceedings in the USPTO

United States Patent and Trademark Office. Patent Trial and Appeal Board

AIA Post-Grant Implementation Begins - Is Your Business Strategy Aligned? August 27, A Web conference hosted by Foley & Lardner LLP

Post-Grant Year in Review

PTAB Trial Proceedings and Parallel Litigation: Impact, Strategy & Consequences

DISCLAIMER PETITIONS FILED SalishanPatent Law Conference

Trends In Post-Grant Proceedings Before the PTAB

The New Post-AIA World

Post Grant Review. Strategy. Nathan Frederick Director, IP Services

This Webcast Will Begin Shortly

America Invents Act Implementing Rules. September 2012

Patent Prosecution in View of The America Invents Act. Overview

Post-Grant for Practitioners

A Practical Guide to Inter Partes Review. Strategic Considerations Relating To Termination

Amendments to the Rules of Practice for Trials Before the Patent Trial and Appeal Board

Part V: Derivation & Post Grant Review

USPTO Implementation of the America Invents Act. Janet Gongola Patent Reform Coordinator Direct dial:

AIA Post-Grant Proceedings: Lessons Learned from PTAB and Federal Circuit Decisions

Intellectual Property: Efficiencies in Patent Post-Grant Proceedings

Inter Partes Review vs. District Court Litigation

Friend or Foe: the New Patent Challenge Procedures at the Patent Trial and Appeal Board

2012 Winston & Strawn LLP

IPRs and CBMs : The Good, the Bad, and the Unknown. Seattle Intellectual Property Inn of Court A Presentation by Group 6 April 17, 2014

Presentation to SDIPLA

America Invents Act of 2011 Part 1: Impact on Litigation Strategy Part 2: Strategic Considerations of the FTF Transition

Session 1A: Preparing an IPR Petition Tips from a Petitioner Perspective

Post-Grant Trends: The PTAB Strikes Back

America Invents Act: The Practical Effects of the New USPTO Post-Grant Proceedings

Kill Rate of the Patent Death Squad, and the Elusory Right to Amend in Post-Grant Reviews - Part I of II

Patent Reform State of Play

BCLT Back to School: The New Patent Law Explained (Post-Grant Procedures) Stuart P. Meyer

PROCEDURES FOR INVALIDATING, CLARIFYING OR NARROWING A PATENT IN THE PATENT OFFICE UNDER THE AMERICA INVENTS ACT (AIA)

America Invents Act H.R (Became Law: September 16, 2011) Michael K. Mutter Birch, Stewart, Kolasch & Birch October 11-12, 2011

U.S. Patent and Trademark Office Issues Proposed Rules for Post-Issuance Patent Review under the America Invents Act

How to Handle Complicated IPRs:

Freedom to Operate and the Use of AIA Review

Presented to The Ohio State Bar Association. May 23, 2012

Strategic Use of Post-Grant Proceedings In Light of Patent Reform

SPECIAL REPORT May 2018 SURPREME COURT FINDS USPTO S ADMINISTRATIVE PATENT TRIALS CONSTITUTIONAL AND SETS GROUND RULES FOR THEIR CONDUCT BY THE PTAB

PTAB Proposed Rule Changes: What s In & What s Out?

August 13, Jeff Costakos Vice Chair, IP Litigation Practice Partner, Patent Office Trials Practice

America Invents Act (AIA) Post-Grant Proceedings. Jeffrey S. Bergman Kevin Kuelbs Laura Witbeck

Patent Trial and Appeal Board - Multi-Petition Challenges of a Patent

Re: Response to Proposed Amendments to the Rules of Practice for Trials Before the Patent Trial and Appeal Board, 80 Fed. Reg (August 20, 2015)

How To Fix The Amendment Fallacy

T he landscape for patent disputes is changing rapidly.

What is Post Grant Review?

PATENT PROSECUTION STRATEGIES IN AN AIA WORLD: SUCCEEDING WITH THE CHANGES

How Post Grant Challenges Have Evolved from Proposed Rules to Practice. Prepared by W. Karl Renner Principal & Co Chair of Post Grant Practice

Intersection of Automotive, Aerospace, & Transportation: Practical Strategies for Resolving IP Conflicts in Multi-Supplier Sourcing

Leveraging Post-Grant Patent Proceedings Before the PTAB

America Invents Act (AIA) Post-Grant Proceedings

MOTIONS TO AMEND IN INTER PARTES REVIEW PROCEEDINGS A QUICK REFERENCE

Patent Office Litigation By the Numbers How effective are the new procedures for resolving litigation? And how dangerous are the new procedures to

Post-Grant for Practitioners: 2017 Year in Review

A Survey Of Patent Owner Estoppel At USPTO

Policies of USPTO Director Kappos & U.S. Patent Law Reform

NEW US PATENT CHALLENGE PROCEDURES PROMOTE GLOBAL HARMONISATION, BUT CASUALTIES RUN HIGH

Inter Partes Review Part I: Pretrial

Patent Litigation Strategies Handbook

Patent Practice in View Of PTAB AIA Proceedings

IP CONCLAVE 2010, MUMBAI STRATEGIES WITH US PATENT PRACTICE NAREN THAPPETA US PATENT ATTORNEY & INDIA PATENT AGENT BANGALORE, INDIA

The Limited Ability of a Patent Owner to Amend Claims and Present New Claims in Post-Grant and Inter Partes Reviews

$2 to $8 million AMERICA INVENTS ACT MANAGING IP RISK IN THE NEW ERA OF POST GRANT PROCEEDINGS 7/30/2013 MANAGING RISK UNDER THE AIA

Post-Grant Reviews Before The USPTO

Presented by Karl Fink, Nikki Little, and Tim Maloney. AIPLA Corporate Practice Committee Breakfast Meeting May 18, 2016

Navigating Section 112 Issues in IPR Proceedings: Using Section 112 as a Sword or a Shield

Preparing for and Navigating PTAB Appeals Before the Federal Circuit

AIA: How U.S. PTO Proceedings. are Changing Patent Litigation. Post-Grant Review Under the. Practice. David Hoffman. James Babineau.

CBM Eligibility and Reviewability

PTAB Strategies and Insights

Discovery and Fact Investigation: New Patent Office Procedures under America Invents Act

Sughrue Mion, PLLC Washington, Tokyo, San Diego, Silicon Valley 7/2/2012

Changes to the Claim Construction Standard for Interpreting Claims in Trial. Proceedings Before the Patent Trial and Appeal Board

Post-Grant for Practitioners. Evidentiary Trends at the PTAB (Part 1) May 11, Thomas Rozylowicz Principal. Steve Schaefer Principal

Considerations for the United States

Correction of Patents

America Invents Act: Patent Reform

The Changing Landscape of AIA Proceedings

America Invents Act (AIA) The Patent Reform Law of 2011 Initial Summary

Lessons From Inter Partes Review Denials

America Invents Act: Patent Reform

Where to Challenge Patents? International Post Grant Practice Strategic Considerations Before the USPTO, EPO, SIPO and JPO

Inter Partes Review: At the Intersection of the USPTO and District Court

Post-Grant for Practitioners. Evidentiary Trends at the PTAB Part II: "Paper" Witness Testimony. June 8, Steve Schaefer Principal

Navigating Section 112 Issues in IPR Proceedings: Using Section 112 as a Sword or a Shield

The America Invents Act : What You Need to Know. September 28, 2011

Is Inter Partes Review Set for Supreme Court Review?

Post-grant opposition system in Japan.

No OIL STATES ENERGY SERVICES, LLC, Petitioner, v. GREENE S ENERGY GROUP, LLC, ET AL., Respondents.

TECHNOLOGY & BUSINESS LAW ADVISORS, LLC

Navigating the Post-Grant Landscape

Transcription:

Protecting Biopharmaceutical Innovation Litigation and Patent Office Procedures Janet Gongola, Senior Advisor Office of the Under Secretary and Director Janet.gongola@uspto.gov Direct dial: 571-272-8734

Overview AIA Trial Statistics Tips from the Judges Proposed Rulemaking 2

3973 Total AIA Petitions* Cumulative from 09/16/2012 3578 90% 382 10% 13 0% Total IPR Petitions Total CBM Petitions Total PGR Petitions 3

305 Total AIA Petitions from TC1600* Cumulative from 09/16/2012 303 99% 0 0% 2 1% Total IPR Petitions Total CBM Petitions Total PGR Petitions 4

AIA Petitions Filed by Fiscal Year by Type PGR CBM IPR 1737 1310 514 177 149 0 8 17 48 0 2 11 FY 2012 FY 2013 FY 2014 FY 2015* 5

AIA Petitions Filed by Fiscal Year by Type from TC1600 PGR CBM IPR 165 91 44 0 0 3 0 0 1 0 1 0 FY 2012 FY 2013 FY 2014 FY 2015* 6

IPR - Decisions On Institution Per Fiscal Year by Outcome CBM - Decisions On Institution Per Fiscal Year by Outcome 15 116 1 10 10 167 26 557 193 801 426 0 14 3 30 91 91 43 FY 2013 FY 2014 *FY 2015 Instituted Joinders Denials FY 2013 FY 2014 *FY 2015 Instituted Joinders Denials PGR - Decisions On Institution Per Fiscal Year by Outcome 3 0 0 0 0 0 FY 2013 FY 2014 *FY 2015 Instituted Joinders Denials 7

IPR - Decisions On Institution Per Fiscal Year by Outcome for TC1600 5 1 0 36 17 49 49 16 2 FY 2013 FY 2014 *FY 2015 Instituted Joinders Denials 8

IPR - Settlements CBM - Settlements 275 32 189 21 106 104 14 20 18 3 0 6 FY 2013 FY 2014 FY 2015* Settled Before Institution Settled After Institution FY 2013 FY 2014 FY 2015* Settled Before Institution Settled After Institution PGR - Settlements 2 0 0 0 0 0 FY2013 FY 2014 FY 2015* Settled Before Institution Settled After Institution 9

IPR Settlements for TC1600 PGR Settlements for TC1600 29 1 14 7 6 0 0 0 0 0 0 0 FY 2013 FY 2014 FY 2015* FY2013 FY 2014 FY 2015* Settled Before Institution Settled After Institution Settled Before Institution Settled After Institution 10

Disposition of IPR Petitions Completed to Date* 1063 Trials Not Instituted Petition Denied/ Settled/ Dismissed 2059 Total Petitions 996 Trials Instituted 421 Terminated During Trial Settled/Dismissed/Requ est for Adverse Judgment 575 Trials Completed Reached Final Written Decisions 414 Trials All Instituted Claims Unpatentable (20% of Total Petitions, 42% of Trials Instituted, 72% of Final Written Decisions) 85 Trials Some Instituted Claims Unpatentable (4% of Total Petitions, 9% of Trials Instituted, 15% of Final Written Decisions) 76 Trials No Instituted Claims Unpatentable (4% of Total Petitions, 8% of Trials Instituted, 13% of Final Written Decisions) 11

Disposition of IPR Petitions Completed to Date for TC1600* 103 Trials Not Instituted Petition Denied/ Settled/ Dismissed 173 Total Petitions 70 Trials Instituted 24 Terminated During Trial Settled/Dismissed/Requ est for Adverse Judgment 46 Trials Completed Reached Final Written Decisions 23 Trials All Instituted Claims Unpatentable (13% of Total Petitions, 33% of Trials Instituted, 50% of Final Written Decisions) 5 Trials Some Instituted Claims Unpatentable (3% of Total Petitions, 7% of Trials Instituted, 11% of Final Written Decisions) 18 Trials No Instituted Claims Unpatentable (10% of Total Petitions, 26% of Trials Instituted, 39% of Final Written Decisions) 12

Disposition of PGR Petitions Completed to Date* 2 Trials Not Instituted Petition Denied/ Settled/ Dismissed 2 Total Petitions 0 Trials Instituted 0 Terminated During Trial Settled/Dismissed/Req uest for Adverse Judgment 0 Trials Completed Reached Final Written Decisions 0 Trials All Instituted Claims Unpatentable (0% of Total Petitions, 0% of Trials Instituted, 0% of Final Written Decisions) 0 Trials Some Instituted Claims Unpatentable (0% of Total Petitions, 0% of Trials Instituted, 0% of Final Written Decisions) 0 Trials No Instituted Claims Unpatentable (0% of Total Petitions, 0% of Trials Instituted, 0% of Final Written Decisions) 13

Disposition of PGR Petitions Completed to Date for TC1600* 1 Trials Not Instituted Petition Denied/ Settled/ Dismissed 1 Total Petitions 0 Trials Instituted 0 Terminated During Trial Settled/Dismissed/Req uest for Adverse Judgment 0 Trials Completed Reached Final Written Decisions 0 Trials All Instituted Claims Unpatentable (0% of Total Petitions, 0% of Trials Instituted, 0% of Final Written Decisions) 0 Trials Some Instituted Claims Unpatentable (0% of Total Petitions, 0% of Trials Instituted, 0% of Final Written Decisions) 0 Trials No Instituted Claims Unpatentable (0% of Total Petitions, 0% of Trials Instituted, 0% of Final Written Decisions) 14

Disposition of CBM Petitions Completed to Date* 116 Trials Not Instituted Petition Denied/ Settled/ Dismissed 242 Total Petitions 126 Trials Instituted 49 Terminated During Trial Settled/Dismissed/Requ est for Adverse Judgment 77 Trials Completed Reached Final Written Decisions 63 Trials All Instituted Claims Unpatentable (26% of Total Petitions, 50% of Trials Instituted, 82% of Final Written Decisions) 11 Trials Some Instituted Claims Unpatentable (5% of Total Petitions, 9% of Trials Instituted, 14% of Final Written Decisions) 3 Trials No Instituted Claims Unpatentable (1% of Total Petitions, 2% of Trials Instituted, 4% of Final Written Decisions) 15

IPR Petitions Terminated to Date* 1196 Claims Found Patentable by PTAB in Final Written Decision 4499 Claims Remaining Patentable (Not Subject to Final Written Decision) 1577 Claims Cancelled or Disclaimed by Patent Owner 17778 Claims Challenged but Not Instituted 33206 Claims Not Challenged 64417 31211 13433 6161 Total Number of Claims Available to be Challenged within 2059 Petitions Claims Challenged Claims Instituted Claims Found Unpatentable by PTAB in Final Written Decision 16

IPR Petitions Terminated to Date for TC1600* 243 Claims Found Patentable by PTAB in Final Written Decision 296 Claims Remaining Patentable (Not Subject to Final Written Decision) 133 Claims Cancelled or Disclaimed by Patent Owner 1852 Claims Challenged but Not Instituted 2546 Claims Not Challenged 5450 2904 1052 380 Total Number of Claims Available to be Challenged within 173 Petitions Claims Challenged Claims Instituted Claims Found Unpatentable by PTAB in Final Written Decision 17

CBM Petitions Terminated to Date* 60 Claims Found Patentable by PTAB in Final Written Decision 834 Claims Remaining Patentable (Not Subject to Final Written Decision) 121 Claims Cancelled or Disclaimed by Patent Owner 2636 Claims Challenged but Not Instituted 3676 Claims Not Challenged 8651 4975 2339 1324 Total Number of Claims Available to be Challenged within 242 Petitions Claims Challenged Claims Instituted Claims Found Unpatentable by PTAB in Final Written Decision 18

Tips from the Judges: Ways Bio-Pharma Patent Owners (PO) Could Strengthen their Filings Point out any issues regarding: o 315(b): whether the Petitioner was served with compliant alleging infringement more than 1 year before petition filing o 325(d): whether the same or substantially the same prior art or arguments previously were presented o real parties-in-interest o claim construction, especially if any differs from those proposed by Petitioner 19

Tips from the Judges: Ways Bio-Pharma Patent Owners (PO) Could Strengthen their Filings Point out: o if asserted prior art is not prior art or PO can swear behind 102(a) art o if a ground fails to address a limitation of a claim o if a ground fails to articulate a reason to combine references o if there may not be a reasonable expectation of success in combining the references because bio-pharma is an unpredictable art But must provide evidence that art is unpredictable, not just make the argument Preferring a declaration merely stating art is unpredictable is not sufficient 20

Tips from the Judges: Ways Bio-Pharma Patent Owners (PO) Could Strengthen their Filings Consider doing due diligence on your relevant patent portfolio, in view of commercial products and regulatory approval, before filing a patent infringement suit Make sure you have narrowest to broadest claims covering relevant commercial products (yours and competitors) to help ensure that if broad claims get knocked out later, you still have claim coverage Consider reexam or reissue before anyone thinks to file an IPR, especially to obtain less broad but viable claims 21

Tips from the Judges: Common PO Mistakes Claim construction: Support with citation to intrinsic evidence; and Be careful about proposing a construction that contradicts a construction previously proposed or adopted by a court Inherency: Explain and cite evidence as to why a limitation at issue would not necessarily exist or be natural result Expert declarations: Make sure they cite evidence 22

Tips from the Judges: Common PO Mistakes Obviousness: Explain why things would not have been obvious to try and cite evidence why something would not have been routine optimization Secondary considerations: provide evidence, including evidence of nexus between the different considerations and what s patentable in the claims (vs. already known in the art) 23

Proposed AIA Trial Rulemaking Allow patent owners to include, with their opposition to a petition to institute a proceeding, new testimonial evidence such as expert declaration New requirement on practitioners before the PTAB, akin to the Rule 11 requirements in federal courts, that would give the USPTO a more robust means with which to police misconduct Clarifies that the PTAB will use the claim construction standard used by district courts for patents that will expire during proceedings and therefore cannot be amended, while confirms the use of broadest reasonable interpretation (BRI) for all other cases Notes the PTAB s development of motions-to-amend practice through its own body of decisions Uses a word count for major briefing 24

Motions-to-Amend MasterImage 3D, Inc. v. RealD Inc., Case IPR2015-00040 (PTAB July 15, 2015) (Paper 42) (representative) Clarified earlier Idle Free decision Patent Owner must show patentable distinction over prior art of record (in the proceeding; in the prosecution history; in any other proceeding involving the same patent) Duty of candor and good faith in the Office may lead to additional prior art made of record by the Patent Owner when moving to amend 25

Possible Single Judge Institution Pilot Single APJ would decide whether to institute an IPR trial, If instituted, two additional APJs would be assigned to conduct trial 26

Public Feedback Proposed AIA Trial Rules Comments due by November 18, 2015 trialrules2015@uspto.gov Possible Single Judge Institution Pilot Comments due by October 26, 2015 ptabtrialpilot@uspto.gov

Questions? Janet Gongola, Senior Advisor Office of the Under Secretary and Director Janet.gongola@uspto.gov Direct dial: 571-272-8734